While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

There are statutory and professional obligations relating to medicine safety: Practices should consider informing all patients about the importance of telling their clinicians about any prescribed and ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

There is no medication specifically for intrusive thoughts, but drugs that alleviate the underlying cause may also reduce the intrusive thoughts. Various conditions can cause intrusive thoughts ...

Wegovy (semaglutide) is a prescription drug used for weight loss and to lower risk of cardiovascular problems. The drug comes as a liquid solution for injection under your skin. It’s usually ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...